2Chapman DP, Perry GS. Depression as a major component ofpublic health for older adults. Prev Chronic Dis, 2008,5(1): A22.
3Gupta S,Goren A,Dong P, et al. Prevalence, awareness,and burden of major depressive disorder in urban China. Ex-pert Rev Pharmacoecon Outcomes Res,2016,16 (3):393-407.
4Krystal JH, Karper LP, Seibyl JP, et al. Subanestheticeffects of the noncompetitive NMOA antagonist, ketamine,in humans. Psychotomimetic, perceptual, cognitive, andneuroendocrine responses. Arch Gen Psychiatry, 1994,51(3): 199-214.
5Abdallah CG,Fasula M, Kelmendi B,et al. Rapid antide-pressant effect of ketamine in the electroconvulsive therapysetting. J ECT, 2012,28(3) : 157-161.
6Rasmussen KG, Kung S,Lapid MI, et al. A randomizedcomparison of ketamine versus methohexital anesthesia in e-lectroconvulsive therapy. Psychiatry Re、s,2014, 215(2):362-365.
7Berman RM, Cappiello A, Anand A,et al. Antidepressanteffects of ketamine in depressed patients. Biol Psychiatry,2000, 47(4): 351-354.
8Jarventausta K,Chrapek W, Kampman (), et al. Effects ofS-ketamine as an anesthetic adjuvant to propofol on treatmentresponse to electroconvulsive therapy in treatment-resistantdepression: a randomized pilot study. J ECT, 2013, 29(3):158-161.
9Zhang JC,Li SX,Hashimoto K. R (-)-ketamine shows grea-ter potency and longer lasting antidepressant effects than S(+ )-ketamine. Pharmacol Biochem Behav, 2014,116:137-141.
10Yang C, ShirayamaY,Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimeticside effects. Transl Psychiatry, 2015,5: e632.
